Microneedle-Based transdermal drug delivery system: Current challenges and Future perspectives: A Review

Over the past few decades, transdermal drug delivery systems (TDDS) have attracted significant interest as a viable alternative to oral and injectable 'formulations due to their ability to provide sustained drug release, bypass first-pass metabolism, and enhance patient compliance. However, the efficacy of traditional transdermal delivery is greatly hindered by the stratum corneum, the skin's outermost layer, which serves as a highly effective barrier to the penetration of most therapeutic agents.[1] To address this challenge, microneedle (MN) technology has emerged as an innovative and minimally invasive platform for transdermal drug delivery. Microneedles are microscopic, needle-shaped structures measuring 25 to 2000 μm in length that form temporary microchannels through the stratum corneum without stimulating pain receptors or causing significant tissue damage. This distinctive method merges the superior delivery efficiency of hypodermic injections with the convenience and patient-friendly attributes of transdermal patches. Based on their design, microneedles are categorized into solid, coated, hollow, dissolving, and hydrogel-forming systems, each providing unique benefits for delivering diverse therapeutic agents such as small molecules, peptides, proteins, vaccines, and biologics [2].Transdermal drug delivery has developed from old topical treatments to advanced medical devices that allow for controlled and effective delivery of medication through the skin [3].In recent decades, progress in microfabrication and material science has led to the development of microneedle (MN) technologies, marking a significant advancement that addresses the shortcomings of oral and traditional injectable drug delivery methods [4].This technology allows for nearly painless, minimally invasive administration of various drugs and biological agents, which enhances patient adherence and improves treatment results[5] Microneedles (MNs) are composed of arrays of microscopic projections, typically less than 1000 µm in length. Upon application, these projections create temporary microchannels in the stratum corneum, enabling efficient delivery of therapeutic agents either into the skin layers or across the skin for localized or systemic treatment [6].

Microneedles are microscopic solid or hollow needle-like structures designed for minimally invasive drug delivery. They generally range from 50 to 900 µm in length and have an outer diameter of 300 µm or less, enabling them to penetrate the outer layer of the skin while minimizing pain and tissue damage [7].

 

 

Fig.No.1: - Microneedle Transdermal Drug Delivery System

Fabrication Techniques: -

The performance, mechanical properties, and clinical applicability of microneedles (MNs) are strongly influenced by their fabrication method. Depending on the intended microneedle type such as solid, coated, dissolving, hollow, or hydrogel-forming an appropriate manufacturing technique must be selected to achieve the desired geometry, mechanical strength, drug-loading capacity, reproducibility, and production cost. Advances in microfabrication technologies over the past two decades have enabled the production of highly precise and reproducible microneedle arrays, supporting their transition from laboratory research to commercial biomedical applications [33,34].

A. Photolithography: -

Photolithography is a well-established microfabrication technique widely employed for the production of solid and coated microneedles. The process involves transferring a predefined pattern onto a photosensitive material deposited on silicon or metal substrates, followed by selective etching to create the desired structures. This method provides excellent dimensional accuracy and uniformity, making it highly suitable for research and prototype development. However, its complex processing steps, specialized equipment, and high manufacturing costs limit its large-scale industrial application [34].

B. Micromolding: -

Micromolding is one of the most commonly used techniques for fabricating dissolving and hydrogel-forming microneedles. In this approach, flexible Molds, typically prepared from polydimethylsiloxane (PDMS), are filled with a drug-containing polymer solution. After curing or drying, the formed microneedle arrays are carefully removed from the Mold. This technique offers excellent reproducibility, is cost-effective, and is compatible with biodegradable polymers, making it suitable for both laboratory research and commercial manufacturing [33].

C. Laser Ablation: -

Laser ablation employs a highly focused laser beam to selectively remove material from metal or polymer substrates, thereby creating microneedles with precise geometries. The technique enables rapid design modification and is particularly useful for prototype development because it does not require dedicated Molds or masks. Nevertheless, the high thermal energy generated during processing may produce surface roughness or heat-related defects, often requiring additional finishing procedures to improve surface quality [34].

D. Three-Dimensional (3D) Printing: -

Three-dimensional (3D) printing has significantly expanded the possibilities for microneedle fabrication through layer-by-layer additive manufacturing. This technology allows the production of complex and customized microneedle architectures with minimal material waste. It also supports the fabrication of multi-material systems and the incorporation of functional components such as drug reservoirs or biosensors within the microneedle structure. Although printing resolution differs among available systems, continuous technological improvements are steadily enhancing the precision and quality of printed microneedles [33].

E. Microelectromechanical Systems (MEMS) Fabrication: -

Microelectromechanical systems (MEMS) technology is an advanced microfabrication approach used to manufacture highly accurate and reproducible silicon-based microneedle arrays. The technique is particularly valuable for diagnostic devices and biosensor-integrated microneedles because it enables the integration of mechanical structures with electronic components. MEMS fabrication provides excellent dimensional control, structural reliability, and compatibility with multifunctional biomedical devices, making it an attractive platform for next-generation microneedle systems [32].

Application of microneedle: -

1)Delivery of Low Molecular Weight Drugs: -

Microneedle (MN) technology has been widely explored to improve the transdermal administration of low molecular weight drugs by overcoming the barrier function of the stratum corneum. Arshad and co-workers demonstrated the successful delivery of the hydrophilic drug cetirizine hydrochloride using dissolving microneedle patches prepared from chitosan and sodium alginate through centrifugation and vacuum micromoulding techniques. In vitro permeation studies using rat skin showed approximately a two-fold increase in drug permeation compared with patches lacking microneedles. Histological analysis further confirmed temporary disruption of the stratum corneum, indicating the effectiveness of the microneedle system in enhancing drug transport across the skin [35].

Similarly, enhanced transdermal delivery of lornoxicam was achieved using a cellulosic microsponge gel applied after microneedle pretreatment. In this approach, the skin was micropunctured with a dermaroller before application of the gel containing the permeation enhancer Transcutol® P. Evaluation in a rat paw oedema model demonstrated significantly greater drug permeation through microneedle-treated skin than untreated skin, resulting in approximately 72% reduction in inflammation within four hours [36].

2)Protein and Peptide Delivery: -

Microneedle (MN) technology has shown significant potential for the transdermal delivery of therapeutic proteins and peptides, particularly for localized treatment with minimal systemic exposure. One important application involves the targeted delivery of peptides that modulate calcitonin gene-related peptide (CGRP), a neuropeptide associated with the development and maintenance of neuropathic pain.

Xie et al. developed a dissolving microneedle patch using sodium carboxymethyl cellulose (SCMC) as the matrix material and incorporated CGRP8–37, a peptide antagonist of CGRP. The therapeutic performance of the formulation was evaluated in rat models of diabetes-induced neuropathy, peripheral nerve injury, and neuropathic pain. The microneedle patch produced localized analgesic effects while preserving normal pain sensation, demonstrating its potential as a targeted treatment strategy for neuropathic pain [37].

In another study, Liu et al. employed polyethylene glycol diacrylate (PEGDA) as the microneedle matrix to investigate peptide/protein delivery, further highlighting the versatility of microneedle platforms for the controlled transdermal administration of biomacromolecules [38].

3) Delivery of Vaccines: -

Microneedle (MN)-based systems have gained considerable attention as an alternative approach for vaccine administration because they enable minimally invasive, painless, and efficient delivery through the skin. Unlike conventional injectable vaccines, which are generally administered by hypodermic needles and may reduce patient acceptance, microneedles offer improved compliance and the possibility of self-administration. These advantages make them particularly valuable for large-scale vaccination campaigns and emergency situations such as the COVID-19 pandemic, especially in resource-limited settings [39].

Arshad et al. demonstrated successful transdermal delivery of the Bacillus Calmette–Guérin (BCG) vaccine using dissolving sodium alginate-based microneedle patches. Immunization studies in rats showed elevated IgG antibody levels after nine weeks, confirming that the microneedle system effectively elicited an immune response [40].

In another investigation, microneedle patches prepared from chitosan, polyvinyl alcohol (PVA), and polyvinylpyrrolidone (PVP) were used to deliver ovalbumin as a model antigen. The formulation provided sustained antigen release for approximately 28 days and maintained high antibody levels in immunized rats for up to 18 weeks. Compared with administration of free antigen or chitosan solution, the ovalbumin-loaded microneedle patches produced a stronger and more prolonged immune response, highlighting the potential of microneedle technology for enhanced vaccine delivery [41].

4) Cancer Therapy: -

Microneedle-based drug delivery systems have emerged as a promising platform for localized combination chemotherapy. One innovative approach involved the development of a three-dimensional, Christmas tree-shaped microneedle array designed to deliver the multi-drug chemotherapy regimen FOLFIRINOX, which consists of fluorouracil, leucovorin, irinotecan, and oxaliplatin. The microneedle arrays were produced using 3D printing technology, with oxaliplatin and leucovorin incorporated into the upper layer, while fluorouracil and irinotecan were loaded into the lower layer. This layered configuration enabled controlled, site-specific release of multiple anticancer agents from a single device. The fabricated microneedles also exhibited strong skin adhesion, demonstrating their potential as an effective transdermal platform for combination therapy in the treatment of pancreatic cancer [42].

Current Challenges in Large-Scale Manufacturing of Microneedle-Based Transdermal Drug Delivery Systems: -

1. Consistent Manufacturing Quality: -

• Ensure uniform microneedle geometry (height, tip sharpness, spacing).
• Prevent dimensional variations during mass production.
• Maintain consistent:
  • Mechanical strength
  • Skin penetration efficiency
  • Drug delivery performance
• Even minor defects can reduce therapeutic effectiveness [43].

2. Limited Scalability of Fabrication Techniques: -

• Photolithography and MEMS-based fabrication
  • High precision
  • Expensive
  • Low production throughput
  • Complex processing steps
• Micromolding and Injection moulding
  • More suitable for industrial production
  • Require optimization for:
    • Faster production
    • Better Mold durability
    • Higher manufacturing efficiency [44].

3. Uniform Drug Loading

• Maintaining the same amount of drug in every microneedle array is difficult during large-scale production.
• Variations may occur because of:
  • Uneven coating thickness
  • Inconsistent polymer casting
• These inconsistencies can lead to:
  • Dose variation
  • Reduced product quality
  • Variable therapeutic effectiveness [43].

4. Material Selection

• Microneedle materials must possess:
  • High mechanical strength
  • Biocompatibility
  • Biodegradability (for dissolving systems)
• Small changes in polymer composition or manufacturing conditions may affect:
  • Mechanical strength
  • Needle integrity
  • Dissolution rate
• Consistent material properties across production batches are essential [45].

5. Sterility and Sterilization

• Pharmaceutical microneedles must be produced under aseptic conditions or sterilized before packaging.
• Common sterilization methods include:
  • Gamma irradiation
  • Steam sterilization
  • Ethylene oxide sterilization
• These methods may:
  • Alter polymer properties
  • Reduce the stability of proteins, peptides, and vaccines
• Developing sterilization methods that preserve both device integrity and drug activity remains a major challenge [43].

Safety Considerations and Clinical Translation Challenges of Microneedle-Based Transdermal Drug Delivery Systems: -

The advancement of microneedle (MN)-based transdermal drug delivery systems has opened new possibilities for painless, self-administered, and patient-friendly drug administration. Despite remarkable progress in laboratory and preclinical investigations, successful clinical translation requires comprehensive evaluation of safety, reliability, regulatory compliance, and long-term therapeutic performance. Several critical factors continue to influence the transition of microneedle technologies from experimental platforms to clinically approved products [46,47].

1. Skin Compatibility and Local Tissue Response: -

Since microneedles overcome the skin barrier by creating temporary microchannels within the stratum corneum, evaluation of skin safety is a fundamental requirement. Short-term effects such as mild redness, swelling, itching, or localized irritation have been reported following application; however, these responses are generally reversible and disappear within a short duration. For repeated administration, further studies are required to assess possible long-term effects, including chronic inflammation, sensitization, and alterations in skin integrity [46,48].

2 Biomaterial Safety and Biocompatibility; -

The selection of appropriate microneedle materials plays a crucial role in ensuring patient safety. Various materials, including silicon, metals, ceramics, and biodegradable polymers, have been investigated for microneedle fabrication. Among these, polymeric microneedles have gained considerable attention due to their biodegradability, reduced risk of sharp waste generation, and suitability for controlled drug release. Nevertheless, comprehensive evaluation of material toxicity, degradation products, and immune responses is essential before clinical application [47,49].

3. Mechanical Stability and Application Reliability: -

For effective and safe drug delivery, microneedles must possess sufficient mechanical strength to penetrate the skin without bending, breaking, or losing structural integrity. Mechanical failure may result in incomplete drug administration or retention of fragments within the skin, which could compromise patient safety. Therefore, optimization of needle geometry, polymer composition, fabrication processes, and mechanical testing methods is necessary to ensure consistent clinical performance [46,48].

4. Sterility and Risk of Microbial Infection: -

Although microneedle-induced microchannels typically close rapidly after application, temporary disruption of the skin barrier may create a potential pathway for microbial entry. Maintaining sterility throughout manufacturing, storage, and administration is therefore essential. The development of suitable sterilization techniques that preserve both drug stability and microneedle structure remains an important challenge, particularly for sensitive biological molecules such as vaccines, proteins, and peptides [47,50].

5. Limited Clinical Evidence and Long-Term Safety Assessment: -

Although numerous microneedle systems have demonstrated promising results in animal studies and early clinical investigations, extensive human trials are still limited for many applications. Large-scale, well-controlled clinical studies are required to establish long-term safety, therapeutic effectiveness, dose consistency, and performance among diverse patient populations before widespread clinical adoption [46,48].

6. Regulatory Pathway and Product Approval Challenges: -

The regulatory approval of microneedle-based products remains complex because these systems often represent a combination of pharmaceutical formulations and medical devices. Differences in regulatory classification between countries create challenges related to quality requirements, manufacturing standards, clinical evaluation, and approval procedures. Establishing internationally accepted regulatory frameworks will be essential to accelerate commercialization of microneedle technologies [47,48].

7. Patient Acceptance and Practical Usability: -

One of the major advantages of microneedle technology is improved patient acceptance compared with conventional injections. Reduced pain, minimal invasiveness, and potential for self-administration make microneedle patches attractive for chronic therapies and vaccination programs. However, variations in skin properties, application technique, and user handling may influence drug delivery efficiency. Development of simple application devices and standardized administration procedures will improve reliability in clinical settings [46,49].

8. Economic and Commercial Considerations: -

The transition of microneedle systems into healthcare practice also depends on economic feasibility. High costs associated with precision manufacturing, sterilization, packaging, and quality control may limit large-scale adoption. Advances in scalable manufacturing technologies and cost-efficient production strategies are required to make microneedle-based products commercially competitive with conventional drug delivery approaches [47,48].

Future Perspectives and Emerging Trends: -

Microneedle (MN) technology is anticipated to progress from a conventional transdermal drug delivery platform to an integrated system capable of drug administration, biomarker sensing, and real-time health monitoring. The convergence of microneedles with wearable biosensors and digital healthcare technologies is expected to facilitate continuous analysis of interstitial fluid biomarkers, enabling early disease detection, personalized therapy, and point-of-care diagnostics [51,52].

Recent research has highlighted the growing interest in stimuli-responsive microneedles that can modulate drug release in response to physiological cues such as glucose levels, pH, temperature, enzyme activity, or inflammatory mediators. These smart systems have the potential to enhance therapeutic precision while minimizing systemic adverse effects, making them particularly promising for the treatment of diabetes, cancer, and chronic inflammatory disorders [51].

The incorporation of artificial intelligence (AI) and machine learning (ML) into microneedle technology is emerging as an important area of research. AI-based computational tools can support the optimization of microneedle geometry, material selection, drug-loading capacity, and release behavior. Furthermore, AI-driven analysis of biosensor data may enable automated decision-making and personalized, closed-loop drug delivery systems [53,54].

Another significant trend is the development of microelectronic and wearable microneedle platforms that integrate sensing components, wireless communication, and controlled drug delivery within a single device. Such multifunctional systems enable continuous physiological monitoring, remote patient management, and improved treatment adherence, thereby supporting next-generation digital healthcare [55,56].

Although remarkable progress has been achieved, several obstacles continue to limit widespread clinical application. Key challenges include large-scale and cost-effective manufacturing, reproducible fabrication, sterilization, long-term mechanical and biological safety, quality assurance, regulatory approval, and commercialization. Addressing these issues will require coordinated efforts among researchers, clinicians, industry partners, and regulatory authorities to ensure successful clinical translation [51,57].

Overall, continuous advances in biomaterials, nanotechnology, wearable electronics, biosensing, and artificial intelligence are expected to expand the capabilities of microneedle systems beyond drug delivery. These innovations are likely to play a crucial role in personalized medicine, disease diagnosis, vaccination, and precision therapeutics in the coming years [51,53].

CONCLUSION

Microneedle technology has emerged as one of the most promising approaches for transdermal drug delivery by overcoming the limitations of conventional oral, topical, and injectable dosage forms. Its minimally invasive nature, improved patient compliance, and ability to deliver a wide range of therapeutic agents, including small molecules, peptides, proteins, vaccines, and nucleic acids, make it an attractive platform for modern healthcare. Continuous advancements in biomaterials, fabrication techniques, and drug-loading strategies have significantly enhanced the safety, efficiency, and versatility of microneedle systems.espite these advantages, several challenges remain before microneedle-based products can achieve widespread clinical use. Large-scale manufacturing, cost-effective production, sterilization, long-term safety, regulatory approval, and quality standardization continue to be major barriers to commercialization. Addressing these challenges will require close collaboration among researchers, clinicians, manufacturers, and regulatory authorities.Overall, the future of microneedle technology extends beyond drug delivery alone. The integration of microneedles with nanotechnology, wearable biosensors, artificial intelligence, and personalized medicine is expected to transform disease diagnosis, continuous health monitoring, and precision therapy. With ongoing scientific and technological progress, microneedle-based systems have the potential to become an important component of next-generation healthcare and significantly improve patient outcomes.

REFERENCES

1. Alkilani AZ, Nasereddin J, Hamed R, et al. Beneath the skin: a review of current trends and future prospects of transdermal drug delivery systems. Pharmaceutics. 2022;14(6):1152. doi:10.3390/pharmaceutics14061152.
2. Parhi R. Recent advances in microneedle designs and their applications in drug and cosmeceutical delivery. J Drug Deliv Sci Technol. 2022; 75:103639. doi: 10.1016/j.jddst.2022.103639.
3. Jung JH, Jin SG. Microneedle for transdermal drug delivery: Current trends and fabrication. Pharm Investig. 2021;51(5):503-517. doi:10.1007/s40005-021-00565-4.
4. Chen K, Sun X, Liu Y, Li S, Meng D. Advances in clinical applications of microneedle. Front Pharmacol. 2025; 16:1607210. doi:10.3389/fphar.2025.1607210.
5. Hulimane Shivaswamy R, Binulal P, Benoy A, Lakshmiramanan K, Bhaskar N, Pandya HJ. Microneedles as a promising technology for disease monitoring and drug delivery: A review. ACS Mater Au. 2025;5(1):115-140. doi:10.1021/acsmaterialsau.4c00131.
6. Arora A, Prausnitz MR, Mitragotri S. Micro-scale devices for transdermal drug delivery. Int J Pharm. 2008;364(2):227-236. doi: 10.1016/j.ijpharm.2008.08.032.
7. Liu T, Chen M, Fu J, et al. Recent advances in microneedles-mediated transdermal delivery of protein and peptide drugs. Acta Pharm Sin B. 2021;11(8):2326-2343. doi: 10.1016/j.apsb.2021.03.003.
8. Donnelly RF, Singh TRR, Woolfson AD. Microneedle-based drug delivery systems: micro-fabrication, drug delivery, and safety. Drug Deliv. 2010;17(4):187-207. doi:10.3109/10717541003667798.
9. van der Maaden K, Jiskoot W, Bouwstra J. Microneedle technologies for (trans)dermal drug and vaccine delivery. J Control Release. 2012;161(2):645-655. doi: 10.1016/j.jconrel.2012.01.042.
10. Pha tale V, Vaiphei KK, Jha S, Patil D, Agrawal M, Alexander A. Overcoming skin barriers through advanced transdermal drug delivery approaches. J Control Release. 2022;351:361-380. doi:10.1016/j.jconrel.2022.09.025.
11. Mansoor etal Arrays of hollow out-of-pvlane microneedles made by metal electrodeposition onto solvent cast conductive polymer structures. J Micromech Microeng. 2013;23(8):085011. doi:10.1088/0960-1317/23/8/085011.
12. Yuan Z, Zhang H, Hu W, Yu X, Qin S, Wang C, Zhang F. State-of-the-art review of metallic microneedles: structure, fabrication, and application. Chin J Mech Eng. 2025; 38:21. doi:10.1186/s10033-025-01188-9.
13. Hsiao YS, Chen CW, Haliq R, Yiu PM, Wu PI, Chu JP. Microfluidic device using metallic nanostructure arrays for the isolation, detection, and purification of exosomes. J Alloys Compd. 2023;947:169658. doi: 10.1016/j.jallcom.2023.169658.
14. Cai B, Xia W, Bredenberg S, Engqvist H. Self-setting bioceramic microscopic protrusions for transdermal drug delivery. J Mater Chem B. 2014;2(36):5992-5998. doi:10.1039/C4TB00764F.
15. Cai B, Xia W, Bredenberg S, Li H, Engqvist H. Bioceramic microneedles with flexible and self-swelling substrate. Eur J Pharm Biopharm. 2015;94:404-410. doi:10.1016/j.ejpb.2015.06.016.
16. Ita K. Ceramic microneedles and hollow microneedles for transdermal drug delivery: Two decades of research. J Drug Deliv Sci Technol. 2018;44:314-322. doi:10.1016/j.jddst.2018.01.004.
17. Narayanan SP, Raghavan S. Fabrication and characterization of gold-coated solid silicon microneedles with improved biocompatibility. Int J Adv Manuf Technol. 2019;100(1-4):61-72. doi:10.1007/s00170-018-2596-3.
18. Tang Y, Li X, Wang Z, et al. Ultra deep reactive ion etching of high aspect-ratio and thick silicon using a ramped-parameter process. J Microelectromech Syst. 2018;27(4):686-688. doi:10.1109/JMEMS.2018.2843722.
19. Dervisevic M, Alba M, Prieto-Simon B, et al. Transdermal electrochemical monitoring of glucose via high-density silicon microneedle array patch. Adv Funct Mater. 2022;32(1):2009850. doi:10.1002/adfm.202009850.
20. urner JG, Larrañeta E, Donnelly RF, et al. antimicrobial releasing hydrogel-forming microneedles. Biomater Adv. 2023;151:213467. doi:10.1016/j.bioadv.2023.213467.
21. Peng K, Mahmood A, Larrañeta E, et al. Hydrogel-forming microneedles for rapid and efficient skin deposition of controlled-release tip implants. Mater Sci Eng C Mater Biol Appl. 2021;127:112226. doi:10.1016/j.msec.2021.112226.
22. Li C, Zhang Y, Wang X, et al. Biomimetic polydopamine loaded with Janus kinase inhibitor for synergistic vitiligo therapy via hydrogel microneedles. J Nanobiotechnology. 2025;23:119. doi:10.1186/s12951-025-03119-1.
23. lfalasi H, Larrañeta E, Donnelly RF, et al. Hydrogel-based microneedles for the delivery of catalase protein. Int J Pharm. 2025;670:125387. doi:10.1016/j.ijpharm.2025.125387.
24. Dardano P, De Stefano L, Rea I, et al. Polymeric microneedle arrays: Versatile tools for an innovative approach to drug administration. Adv Ther (Weinh). 2019;2(9):1900036. doi:10.1002/adtp.201900036.
25. Barrett C, Chaganti K, Gonzales A, et al. Development of low-cost rapid fabrication of sharp polymer microneedles for in vivo glucose biosensing applications. ECS J Solid State Sci Technol. 2015;4(10):S3053-S3058. doi:10.1149/2.0141510jss.
26. Wang Z, Liu Y, Zhang H, et al. A review on recent advances in polymeric microneedle loading cells: Design strategies, fabrication technologies, transdermal applications and challenges. Int J Biol Macromol. 2025; 277:138885. doi: 10.1016/j.ijbiomac.2024.138885.
27. Lee JW, Park JH, Prausnitz MR. Dissolving microneedles for transdermal drug delivery. Biomaterials. 2008;29(13):2113-2124. doi: 10.1016/j.biomaterials.2007.12.048.
28. amiri F, Kommineni N, Ebhodaghe SO, Bulusu R, Jyothi VGSS, Sayed AA, Awaji AA, Germoush MO, Al-Malky HS, Nasrullah MZ, Rahman MdH, Abdel-Daim MM, Berrada M. Microneedle-based natural polysaccharides for drug delivery systems (DDS): Progress and challenges. Pharmaceuticals (Basel). 2022;15(2):190. doi:10.3390/ph15020190.
29. u G, Sun X. Current advances in sustained release microneedles. Pharm Fronts. 2020;2(1):e11-e22. doi:10.1055/s-0040-1701435.
30. ldawood FK, Andar A, Desai S. A comprehensive review of microneedles: types, materials, processes, characterizations and applications. Polymers. 2021;13(16):2815. doi:10.3390/polym13162815.
31. vcil M, Çelik A. Microneedles in drug delivery: progress and challenges. Micromachines. 2021;12(11):1321. doi:10.3390/mi12111321.
32. Cao J, Wu B, Yuan P, Liu Y, Hu C. Advances in research of hydrogel microneedle-based delivery systems for disease treatment. Pharmaceutics. 2024;16(12):1571. doi:10.3390/pharmaceutics16121571.
33. Maia RF, Machado P, Rodrigues RO, Faustino V, Schütte H, Gassmann S, et al. Recent advances and perspectives of microneedles for biomedical applications. Biophys Rev. 2025:1-20. doi:10.1007/s12551-025-01471-z.
34. Abdullah AC, Ahmadinejad E, Tasoglu S. Optimizing solid microneedle design: a comprehensive ML-augmented DOE approach. ACS Meas Sci Au. 2024;4(5):504-514. doi:10.1021/acsmeasuresciau.4c00032.
35. rshad MS, Hassan S, Hussain A, Abbas N, Kucuk I, Nazari K, et al. Improved transdermal delivery of cetirizine hydrochloride using polymeric microneedles. DARU J Pharm Sci. 2019;27(2):673-681. doi:10.1007/s40199-019-00301-3.
36. He Y, Majid K, Maqbool M, et al. Formulation and characterization of lornoxicam-loaded cellulosic microsponge gel for possible applications in arthritis. Saudi Pharm J. 2020;28(8):994-1003. doi: 10.1016/j.jsps.2020.06.014.

37. ie X, Pascual C, Lieu C, Oh S, Wang J, Zou B, et al. Analgesic microneedle patch for neuropathic pain therapy. ACS Nano. 2017;11(1):395-406. doi:10.1021/acsnano.6b06104.
38. Liu S, Yeo DC, Wiraja C, Tey HL, Mrksich M, Xu C. Peptide delivery with poly (ethylene glycol) diacrylate microneedles through swelling effect. Bioeng Transl Med. 2017;2(3):258-267. doi:10.1002/btm2.10070.
39. Arshad MS, Fatima S, Nazari K, Ali R, Farhan M, Muhammad SA, et al. Engineering and characterisation of BCG-loaded polymeric microneedles. J Drug Target. 2020;28(5):525-532. doi:10.1080/1061186X.2019.1693577
40. Zafar S, Arshad MS, Fatima S, et al. COVID-19: Current developments and further opportunities in drug delivery and therapeutics. Pharmaceutics. 2020; 12:1-26. doi:10.3390/pharmaceutics12100945.
41. Chen MC, Lai KY, Ling MH, Lin CW. Enhancing immunogenicity of antigens through sustained intradermal delivery using chitosan microneedles with a patch-dissolvable design. Acta Biomater. 2018; 65:66-75. doi: 10.1016/j.actbio.2017.10.033.
42. Huang D, Fu X, Zhang X, Zhao Y. Christmas tree-shaped microneedles as FOLFIRINOX spatiotemporal delivery system for pancreatic cancer treatment. Research (Wash D C). 2022; 2022:9809417. doi:10.34133/2022/9809417.
43. Nguyen H, Banga AK. Electrically and ultrasonically enhanced transdermal delivery of methotrexate. Pharmaceutics. 2018;10(3):117. doi:10.3390/pharmaceutics10030117.
44. Larrañeta E, Lutton REM, Woolfson AD, Donnelly RF. Microneedle arrays as transdermal and intradermal drug delivery systems: materials science, manufacture and commercial development. Mater Sci Eng R Rep. 2016; 104:1-32. doi: 10.1016/j.mser.2016.03.001.
45. Sheng T, Luo B, Zhang W, Ge X, Yu J, Zhang Y, Gu Z. Microneedle-mediated vaccination: innovation and translation. Adv Drug Deliv Rev. 2021; 179:113919. doi: 10.1016/j.addr.2021.113919.
46. Yu H, Ling Y, Wang Y, et al. Microneedles in drug delivery: Progress and challenges. Pharmaceutics. 2021;13(11):1902. doi:10.3390/pharmaceutics13111902.
47. Larrañeta E, McCrudden MTC, Courtenay AJ, Donnelly RF. Microneedles: A new frontier in nanomedicine delivery. Pharm Res. 2016;33(5):1055-1073. doi:10.1007/s11095-016-1885-5.
48. Nguyen HX, Banga AK. Advanced transdermal drug delivery system: A comprehensive review of microneedle technologies, novel designs, diverse applications, and critical challenges. Int J Pharm. 2025; 670:125118. doi: 10.1016/j.ijpharm.2025.125118.
49. Donnelly RF, Singh TRR, Garland MJ, et al. Hydrogel-forming microneedles for enhanced transdermal drug delivery. Adv Funct Mater. 2012;22(23):4879-4890. doi:10.1002/adfm.201200864.
50. Ita K. Transdermal delivery of drugs with microneedles: Potential and challenges. Pharmaceutics. 2015;7(3):90-105. doi:10.3390/pharmaceutics7030090.
51. Zheng M, Sheng T, Yu J, Gu Z, Xu C. Microneedle biomedical devices. Nat Rev Bioeng. 2024; 2:324-342. doi:10.1038/s44222-024-00168-6.
52. ora LK, Sabri AH, McKenna PE, et al. Microneedle-based biosensing. Nat Rev Bioeng. 2024; 2:64-81. doi:10.1038/s44222-023-00144-6.

53. Microneedle biosensors for disease diagnosis: From fabrication to AI enhancement (TrAC Trends Anal Chem.) DOI: 10.1016/j.trac.2026.118731.
54. poorva S, Nguyen NT, Sreejith KR. Recent developments and future perspectives of microfluidics and smart technologies in wearable devices. Lab Chip. 2024; 24:1833-1866. doi:10.1039/D4LC00046G.
55. Advances in microneedles for transdermal diagnostics and sensing applications

DOI: 10.1007/s00604-024-06458-2.

56.  Wang L, Wang Y, Wu X, Wang P, Luo X, Lv S. Advances in microneedles for transdermal diagnostics and sensing applications. Mikrochim Acta. 2024;191(7):406. doi:10.1007/s00604-024-06458-2.
57. Ravindra Babu M, Vishwas S, Gulati M, Dua K, Singh SK. Harnessing the role of microneedles as sensors: Current status and future perspectives. Drug Discov Today. 2024;29(7):104030. doi: 10.1016/j.drudis.2024.104030.